Cargando…
Survival modelling and cost-effectiveness analysis of treatments for newly diagnosed metastatic hormone-sensitive prostate cancer
BACKGROUND: In metastatic hormone-sensitive prostate cancer (mHSPC) treatment, survival benefits have been shown by adding docetaxel or recent androgen receptor axis-targeted therapies (ARATs) abiraterone, apalutamide, or enzalutamide to androgen deprivation therapy (ADT). However, the optimal treat...
Autores principales: | Barbier, Michaela C., Tomonaga, Yuki, Menges, Dominik, Yebyo, Henock G., Haile, Sarah R., Puhan, Milo A., Schwenkglenks, Matthias |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632884/ https://www.ncbi.nlm.nih.gov/pubmed/36327294 http://dx.doi.org/10.1371/journal.pone.0277282 |
Ejemplares similares
-
Systematic early versus late mobilization or standard early mobilization in mechanically ventilated adult ICU patients: systematic review and meta-analysis
por: Menges, Dominik, et al.
Publicado: (2021) -
Net benefit of statins for primary prevention of cardiovascular
disease in people 75 years or older: a benefit–harm balance modeling
study
por: Yebyo, Henock G., et al.
Publicado: (2019) -
Global variation of risk thresholds for initiating statins for primary prevention of cardiovascular disease: a benefit-harm balance modelling study
por: Yebyo, Henock G., et al.
Publicado: (2020) -
Should statin guidelines consider patient preferences? Eliciting preferences of benefit and harm outcomes of statins for primary prevention of cardiovascular disease in the sub-Saharan African and European contexts
por: Yebyo, Henock G., et al.
Publicado: (2018) -
Patient Preference Studies for Advanced Prostate Cancer Treatment Along the Medical Product Life Cycle: Systematic Literature Review
por: Menges, Dominik, et al.
Publicado: (2022)